|Bid||33.20 x 400|
|Ask||33.43 x 500|
|Day's Range||33.26 - 33.49|
|52 Week Range||29.83 - 35.38|
|PE Ratio (TTM)||28.08|
|Dividend & Yield||1.28 (3.83%)|
|1y Target Est||N/A|
Giving credit where credit is due, I do think Valeant Pharmaceuticals Intl Inc (NYSE:VRX) stock looks stronger than it did just a couple of quarters ago. VRX stock has still declined 1.5% so far this year, but the narrative surrounding the company has certainly changed. On the Q2 conference call, Valeant management made a big deal of the fact that 73% of Q2 revenue came from Bausch & Lomb and the Salix business.
Apart from Pfizer’s (PFE) product developments, let's take a look at some recent pipeline and corporate developments.
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Pfizer Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)